Medical Instruments & Supplies · Healthcare
CFO
2023-09-11–present
Equibles does not estimate personal net worth.
Get an email with a short summary when Bionano Genomics, Inc. publishes a filing, an earnings call transcript or a press release.
Get BNGO alertsGülsen Kama is recorded as CFO at Bionano Genomics, Inc. (BNGO) since September 11, 2023. Bionano Genomics, Inc. reported in an 8-K filed September 9, 2024 that Gülsen Kama was terminated as Chief Financial Officer, effective September 18, 2024. Bionano Genomics, Inc. reported in an 8-K filed August 14, 2023 that Gülsen Kama was appointed Chief Financial Officer, effective September 11, 2023. Gülsen Kama has spoken on 4 earnings calls across 1 company, most recently for Bionano Genomics, Inc. on August 7, 2024. Bionano Genomics, Inc. is classified in the Medical Instruments & Supplies industry within the Healthcare sector. Other leadership on record at Bionano Genomics, Inc. includes Albert A. Luderer, Ph.D. (CEO and CFO), R. Erik Holmlin (CEO and Board Member), Albert Luderer (Chairman) and 7 others.
“In connection with the Reduction, the role of our Chief Financial Officer, Gülsen Kama, was impacted and Ms. Kama will no longer be employed with the Company effective September 18, 2024.”
“On August 14, 2023, the Company announced the appointment of Gülsen Kama as Bionano Genomics, Inc.'s (the "Company") Chief Financial Officer, effective as of September 11, 2023 (the "Effective Date").”
“As Erik mentioned, revenue for the quarter was $7.8 million. GAAP gross margin for the second quarter was 33% compared to 27% during Q2 2023 and non-GAAP gross margin was 35% compared to 29% in the same quarter last year.”
“With that, let me share our results for the first quarter of 2024 with you. Revenue was $8.8 million, representing an 18% year-over-year increase compared to the same period of 2023.”
“Consistent with our pre-announcement in January, Q4 revenues were $10.7 million, which is up 30% versus Q4 2022. 2023 revenue totaled $36.1 million, which reflects an increase of 30% over 2022 revenue.”
“I'm pleased to be on board at Bionano and to join the effort to help expand the adoption and utilization of OGM around the world. To achieve that goal, we have to be financially disciplined as we seize the opportunities ahead of us.”
2023-09-11–present
2023-09-11–2024-09-18
Start not stated–2024-09-18
Medical Instruments & Supplies · Healthcare
CFO
2023-09-11–present